Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Somatostatin, secreted from pancreatic -cells, acts as an inhibitory paracrine to suppress glucagon release from pancreatic -cells, and specific blockade of SSRT2 eliminates the inhibitory effect of GLP-1 on glucagon secretion
is a ghrelin mimetic
Product Specifications Compound: Ipamorelin (Selective Ghrelin-Receptor Agonist Analog)Purity: 99% | HPLC VerifiedForm: Lyophilized research compoundStorage: Store in a cool, dark environment below 20 CUsage: For in vitro research and laboratory investigation only Research Interest Areas Information derived from exi
It includes supporting nutrients like alpha lipoic acid
Satiety and Food Intake Reduction Cagrilintide's most clinically significant effect is its potent reduction in food intake and enhancement of satiety through activation of AMY1 receptors in the area postrema [14] : Brainstem Satiety Signaling: Area postrema neurons project to nucleus tractus solitarius (NTS), which integrates peripheral satiety signals and regulates feeding behavior [17] Dose-Dependent Effects: Higher doses of cagrilintide produce greater reductions in ad libitum food intake and increased subjective fullness ratings [9] Sustained Effect: Unlike acute satiety signals, cagrilintide's long half-life provides continuous appetite suppression between weekly doses [2] Synergy with GLP-1 Receptor Agonists The combination of cagrilintide with GLP-1 receptor agonists (particularly semaglutide) produces effects greater than either agent alone
